Lb Pharmaceuticals Inc.
Clinical trials sponsored by Lb Pharmaceuticals Inc., explained in plain language.
-
New hope for schizophrenia: phase 3 drug trial begins
Disease control Recruiting nowThis study tests a new drug, LB 102, to see if it helps reduce schizophrenia symptoms better than a placebo. About 456 adults with acute schizophrenia will take either the drug or a placebo for 6 weeks while staying in the hospital. The main goal is to measure changes in symptoms…
Phase: PHASE3 • Sponsor: LB Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug LB-102 aims to lift bipolar depression
Symptom relief Recruiting nowThis Phase 2 study tests whether LB-102 can reduce depressive symptoms in adults with bipolar I disorder who are currently in a major depressive episode. About 320 participants will receive either the drug or a placebo for 6 weeks. The main goal is to see if LB-102 improves depre…
Phase: PHASE2 • Sponsor: LB Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC